Form 4: Actinium Pharmaceuticals CEO Cancels Stock Options
SEC Form 4
Actinium Pharmaceuticals CEO, Sandesh Seth, cancels multiple stock options effective March 31, 2025, as per an Option Cancellation and Release Agreement.
Summary
- Sandesh Seth, CEO of Actinium Pharmaceuticals, filed a Form 4 on April 02, 2025, reporting the cancellation of several stock options.
- The cancellations were effective March 31, 2025, and were made according to an Option Cancellation and Release Agreement.
- The stock options had various exercise prices, ranging from $4.96 to $59.7.
- The expiration dates for these options ranged from April 15, 2026, to December 28, 2033.
- The total number of underlying common stock shares affected by the cancellation is substantial.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a reporting of a transaction, not inherently positive or negative.
Industry Context
Stock option cancellations can be part of executive compensation restructuring or strategic realignment within a company. It's important to consider this event in the context of Actinium Pharmaceuticals' overall financial health and strategic direction.
Stakeholder Impact
- The cancellation of stock options may affect the perceived value of executive compensation by shareholders.
- Employees holding similar options may be impacted by this decision.
Key Dates
| Date | Description |
|---|---|
| 03/31/2025 | Date of earliest transaction and effective date of stock option cancellations. |
| 04/02/2025 | Date of Form 4 filing. |
| 04/15/2026 | Earliest expiration date of cancelled stock options. |
| 12/28/2033 | Latest expiration date of cancelled stock options. |
Keywords
stock options, Form 4, Actinium Pharmaceuticals, Sandesh Seth, CEO, cancellation, ATNM
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.